http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2581337-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_309dcfe91ff2472d71678e173610b085 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4741 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N25-00 |
| filingDate | 2005-09-22^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30f03abcf2e5e8d4af140ce141ea80a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3521ea7c009a969d17847826e6b4778d |
| publicationDate | 2006-03-30^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2581337-A1 |
| titleOfInvention | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease |
| abstract | Preferred embodiments of the present invention are related to novel therapeutic drugs and drug combinations, and associated methods, for treating and/or preventing complications in patients with diabetes, metabolic syndrome, and/or hypertension. More particularly, aspects of the present invention are related to the use of cicletanine as a monotherapy or in combination with other agents for treatment of disease. Cicletanine, as either a monotherapy or in combination with other drugs, may have the form of a non-racemic mixture of the negative (-) and positive (+) enantiomers of cicletanine, or as either the (-) or (+) enantiomer alone. |
| priorityDate | 2004-09-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 850 of 850.